Tuesday, 3 Oct, 2023

FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants

FDA approves Abrysvo for immunization at 32 through 36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.